Search alternatives:
greater decrease » greatest decrease (Expand Search), greater increase (Expand Search), greater disease (Expand Search)
nn decrease » _ decrease (Expand Search), a decrease (Expand Search), gy decreased (Expand Search)
greater decrease » greatest decrease (Expand Search), greater increase (Expand Search), greater disease (Expand Search)
nn decrease » _ decrease (Expand Search), a decrease (Expand Search), gy decreased (Expand Search)
-
1461
-
1462
-
1463
-
1464
-
1465
-
1466
Table 1_Elevated mean arterial pressure and risk of impaired fasting glucose: a multicenter cohort study revealing age and sex interactions.docx
Published 2025“…Multivariate smooth splines analysis revealed a nonlinear relationship (P for nonlinearity < 0.05), with the curve slope decreasing as MAP exceeded 103.23 mmHg. Significant interaction effects between MAP and age or sex on IFG risk were also identified (P < 0.05).…”
-
1467
-
1468
-
1469
-
1470
Data Sheet 1_Disproportionate impact of the COVID-19 pandemic on socially vulnerable communities: the case of Jane and Finch in Toronto, Ontario.docx
Published 2025“…The number of patients during the COVID-19 pandemic versus before that decreased significantly more for pop-smear tests (p = 0.041) and surgery waitlists (p = 0.037) for the Jane and Finch community.…”
-
1471
-
1472
Summary of study eligibility criteria.
Published 2025“…Considering the high prevalence of BV among African, Caribbean and Black (ACB) women, we conducted a prospective, randomized, open-label phase 1 clinical trial to determine the feasibility, safety and tolerability of administering low-dose estrogen, probiotics or both in combination to improve vaginal health and decrease HIV-1 susceptibility.</p><p>Methods</p><p>ACB women aged 18–49 from the Greater Toronto Area (GTA) were randomized to one of four study arms: intravaginal estradiol (Estring©; 7.5mg/day); a vaginal probiotic (RepHresh™ Pro-B™) administered twice daily; a combination of Estring© and vaginal RepHresh™ Pro-B™ (twice daily); or the Estring© and oral RepHresh™ Pro-B™ (twice daily), for a duration of 30 days. …”
-
1473
Summary of study participation and feasibility.
Published 2025“…Considering the high prevalence of BV among African, Caribbean and Black (ACB) women, we conducted a prospective, randomized, open-label phase 1 clinical trial to determine the feasibility, safety and tolerability of administering low-dose estrogen, probiotics or both in combination to improve vaginal health and decrease HIV-1 susceptibility.</p><p>Methods</p><p>ACB women aged 18–49 from the Greater Toronto Area (GTA) were randomized to one of four study arms: intravaginal estradiol (Estring©; 7.5mg/day); a vaginal probiotic (RepHresh™ Pro-B™) administered twice daily; a combination of Estring© and vaginal RepHresh™ Pro-B™ (twice daily); or the Estring© and oral RepHresh™ Pro-B™ (twice daily), for a duration of 30 days. …”
-
1474
Study variables.
Published 2025“…The mean tree cover percentage also decreased from 21% in 2011 to 19% in 2016. …”
-
1475
Descriptive statistics.
Published 2025“…The mean tree cover percentage also decreased from 21% in 2011 to 19% in 2016. …”
-
1476
-
1477
-
1478
-
1479
-
1480